Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-02-06
2008-11-25
Coleman, Brenda L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S576000
Reexamination Certificate
active
07456165
ABSTRACT:
The invention encompasses compounds of Formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
REFERENCES:
patent: 7153848 (2006-12-01), Hudyma et al.
patent: 2006/0166964 (2006-07-01), Hudyma et al.
patent: 2007/0060565 (2007-03-01), Meanwell et al.
patent: 2007/0078122 (2007-04-01), Bergstrom et al.
patent: 2007/0185083 (2007-08-01), Bergstrom et al.
patent: WO2005/080399 (2005-09-01), None
patent: WO2006/040039 (2006-04-01), None
patent: WO2006/046030 (2006-05-01), None
patent: WO2007/029029 (2007-03-01), None
U.S. Appl. No. 11/752,354, filed May 23, 2007, Robert G. Gentles, et al.
U.S. Appl. No. 11/753,137, filed May 24, 2007, Carl P. Bergstrom.
U.S. Appl. No. 11/756,203, filed May 31, 2007, Kap-Sun Yeung, et al.
Bergstrom Carl P.
Hudyma Thomas W.
Martin Scott W.
Bristol--Myers Squibb Company
Coleman Brenda L
Epperson James
LandOfFree
HCV NS5B inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HCV NS5B inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HCV NS5B inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4042758